Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …

Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Background Data on patients with COVID-19 who have cancer are lacking. Here we
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …

Summary Background Belantamab mafodotin (GSK2857916), an immunoconjugate
targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 …

The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an
infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19 …

Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

The use of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple
myeloma (MM) is showing early promising overall response rates in heavily pretreated …

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA
vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to …

Abstract The European Myeloma Network provides recommendations for the management
of the most common complications of multiple myeloma. Whole body low-dose computed …

In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …